Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb Ischaemia: 12-Month Results of a Prospective Randomised Single-Blinded Non-Inferiority Trial

Zhihui Dong,Tianyue Pan,Yuan Fang,Zheng Wei,Shiyang Gu,Gang Fang,Yifan Liu,Yang Luo,Hao Liu,Tiejun Zhang,Meiyu Hu,Daqiao Guo,Xin Xu,Bin Chen,Junhao Jiang,Jue Yang,Zhenyu Shi,Ting Zhu,Yun Shi,Peng Liu,Weiguo Fu
DOI: https://doi.org/10.1016/j.ebiom.2018.08.038
IF: 11.205
2018-01-01
EBioMedicine
Abstract:Background: Peripheral blood mononuclear cells (PBMNCs) and purified CD34(+) cells (PCCs) are increasingly being used at treating no-option critical limb ischaemia (NO-CU). We aimed to compare the efficacies and uncover the advantages associated with each treatment approach. Methods: A randomised single-blinded non-inferiority trial (Number: NCT02089828) was performed. NO-CLI patients were 1:1 randomised to the PBMNCs and PCCs groups, and compared in relation to safety and efficacy outcomes. The primary efficacy outcomes included major amputation and total amputation over 12 months. The major amputation-free survival (MAFS) and total amputation-free survival (TAFS) rates were calculated. Findings: Fifty patients (25 per group, 47 with thromboangiitis obliterans and 3 with other angiitis) were enrolled, with a median follow-up period of 24.5 months (interquartile range: 17-34 months). One patient in the PCCs group was lost at 2 months and one major amputation occurred in the PBMNCs group at 3 months post-transplantation. The total amputation rates at 6 months post-transplantation were 28.0% in the PCCs group and 16.0% in the PBMNCs group (p = 0.343), and remained unchanged at 12 months. The groups did not differ regarding the MAFS and TAB (Breslow-Wilcoxon test: p = 03014 and p = 0.3414). The PCCs group had a significantly higher probability of rest pain relief than the PBMNCs group (Breslow-Wilcoxon test: p = 0.0454). Interpretation: PCCs was not inferior to PBMNCs at limb salvage in the treatment of angiitis-induced NO-CU and appeared to induce earlier ischaemia relief. Each cell type had specific advantages. These outcomes require verification from longer-term trials involving larger numbers of patients. (C) 2018 The Authors. Published by Elsevier B.V.
What problem does this paper attempt to address?